Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives

S Yandrapalli, G Andries, M Biswas… - Vascular health and risk …, 2017 - Taylor & Francis
With an estimated prevalence of 5.8 million in the USA and over 23 million people
worldwide, heart failure (HF) is growing in epidemic proportions. Despite the use of …

[引用][C] Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives

S Yandrapalli, G Andries, M Biswas… - Vascular Health and Risk …, 2017 - cir.nii.ac.jp
Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives
| CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …

Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives

S Yandrapalli, G Andries… - Vascular health and …, 2017 - pubmed.ncbi.nlm.nih.gov
With an estimated prevalence of 5.8 million in the USA and over 23 million people
worldwide, heart failure (HF) is growing in epidemic proportions. Despite the use of …

Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives

S Yandrapalli, G Andries, M Biswas… - Vascular Health and …, 2017 - search.proquest.com
With an estimated prevalence of 5.8 million in the USA and over 23 million people
worldwide, heart failure (HF) is growing in epidemic proportions. Despite the use of …

Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives.

S Yandrapalli, G Andries, M Biswas… - Vascular Health and Risk …, 2017 - europepmc.org
With an estimated prevalence of 5.8 million in the USA and over 23 million people
worldwide, heart failure (HF) is growing in epidemic proportions. Despite the use of …

[HTML][HTML] Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives

S Yandrapalli, G Andries, M Biswas… - Vascular Health and …, 2017 - ncbi.nlm.nih.gov
With an estimated prevalence of 5.8 million in the USA and over 23 million people
worldwide, heart failure (HF) is growing in epidemic proportions. Despite the use of …

[PDF][PDF] Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives

S Yandrapalli - Vascular Health and Risk Management, 2017 - pdfs.semanticscholar.org
With an estimated prevalence of 5.8 million in the USA and over 23 million people
worldwide, heart failure (HF) is growing in epidemic proportions. Despite the use of …

Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives

S Yandrapalli, G Andries, M Biswas… - Vascular Health and Risk …, 2017 - go.gale.com
With an estimated prevalence of 5.8 million in the USA and over 23 million people
worldwide, heart failure (HF) is growing in epidemic proportions. Despite the use of …

Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives

S Yandrapalli, G Andries, M Biswas… - Vascular Health and Risk …, 2017 - dovepress.com
With an estimated prevalence of 5.8 million in the USA and over 23 million people
worldwide, heart failure (HF) is growing in epidemic proportions. Despite the use of …

Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives

S Yandrapalli, G Andries, M Biswas… - Vascular Health and …, 2017 - dash.harvard.edu
With an estimated prevalence of 5.8 million in the USA and over 23 million people
worldwide, heart failure (HF) is growing in epidemic proportions. Despite the use of …